ArticleCurrent medicinal chemistry2025
EACVP: An ESM-2 LM Framework Combined CNN and CBAM Attention to Predict Anti-coronavirus Peptides.
Article in Current medicinal chemistry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed, 10 citations in OpenAlex.
- Quantitative Analysis Model for the Powder Content ofFoods (Basel, Switzerland) · 2026Article
- Article
- A deep learning model for anti-inflammatory peptides identification based on deep variational autoencoder and contrastive learning.Scientific reports · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
Abstract
backgroundThe novel coronavirus pneumonia (COVID-19) outbreak in late 2019 killed millions worldwide. Coronaviruses cause diseases such as severe acute respiratory syndrome (SARS-CoV) and SARS-CoV-2. Many peptides in the host defense system have antiviral activity. How to establish a set of efficient models to identify anti-coronavirus peptides is a meaningful study.
methodsGiven this, a new prediction model EACVP is proposed. This model uses the evolutionary scale language model (ESM-2 LM) to characterize peptide sequence information. The ESM model is a natural language processing model trained by machine learning technology. It is trained on a highly diverse and dense dataset (UR50/D 2021_04) and uses the pre-trained language model to obtain peptide sequence features with 320 dimensions. Compared with traditional feature extraction methods, the information represented by ESM-2 LM is more comprehensive and stable. Then, the features are input into the convolutional neural network (CNN), and the convolutional block attention module (CBAM) lightweight attention module is used to perform attention operations on CNN in space dimension and channel dimension. To verify the rationality of the model structure, we performed ablation experiments on the benchmark and independent test datasets. We compared the EACVP with existing methods on the independent test dataset.
resultsExperimental results show that ACC, F1-score, and MCC are 3.95%, 35.65% and 0.0725 higher than the most advanced methods, respectively. At the same time, we tested EACVP on ENNAVIA-C and ENNAVIA-D data sets, and the results showed that EACVP has good migration and is a powerful tool for predicting anti-coronavirus peptides.
conclusionThe results prove that this model EACVP could fully characterize the peptide information and achieve high prediction accuracy. It can be generalized to different data sets. The data and code of the article have been uploaded to https://github.- com/JYY625/EACVP.git.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.